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Purpose or Objective: Intensity modulated radiotherapy 
(IMRT), including helical Tomotherapy (HT), has been only 
recently introduced in the treatment of locally advanced 
rectal cancer (LARC) patients. We retrospectively assessed 
acute toxicity and efficacy of concomitant chemo-
radiotherapy (CRT) delivered with HT and daily image-guided 
RT (IGRT) for non metastatic LARC patients in 2 Swiss 
institutions. 
 
Material and Methods: We analyzed acute grade 3+ toxicity 
(CTC-AE v.4.0) and local control (LC) rates. Late toxicity 3+, 
Overall (OS), disease-free (DFS), and colostomy-free survival 
(CFS) were also studied and reported. Tumor Regression Rate 
(TRG) after CRT was scored using the Mandard score. 
Volumes were defined as follows: CTV1: rectum + 
mesorectum + internal iliac nodes + presacral nodes + 
obturatory nodes. In one of the 2 institutition, a CTV2 was 
also defined: rectal GTV + corresponding mesorectum (with a 
2-cm margin in the cranio-caudal direction) + nodal GTV (if 
N+ patients). Planning target volumes were obtained by 
adding 5-mm margin to the CTV (PTV1 and PTV2, 
respectively). PTV1 received 44-45 Gy (1.8-2 Gy/fraction), 
while PTV2 received a simultaneous integrated boost up to a 
total dose of 50 Gy (2 Gy/fr).  
 
Results: From 01.2010 to 01.2015, 118 patients were treated; 
35, 9, 61, 12 and 1 patients presented a stage II, IIIA, IIIB, IIIC 
and IVa, respectively. Median age was 65 years (range, 32-
85). All patients received concomitant CTX with 
fluoropyrimidine (i.v. or oral). After a median time of 53 days 
(range, 1-142), all patients received a radical surgery. Mean 
follow-up was 21 months (range: 1-62). No Grade 3 acute 
toxicity was observed. Acute grade 1-2 toxicity was observed 
in 22% of patients. Three-years LC, OS, DFS, and CFS rates 
were 95,2%, 82.4%, 83% and 69%, respectively. Median time 
to any progression for relapsing patients was 23 months 
(range: 5-66). At the time of analysis, 108 patients presented 
more than 4 months of followup and were considered 
evaluable for late toxicity. Data about late toxicity were not 
available for 48 patients, followed in other Institutions after 
RT-CT. Looking at the final 60 patients, only 2 of them 
patients presented a late G3 gastrointestinal toxicity (anal 
incontinence). Looking at 3-year LC, at univariate analysis, 
patients operated in the 66 days after the end of the 
treatment (98.8% vs 83.6%, Log-rank test: p = 0.022) and 
those without endovascular invasion at final pathology (98.6% 
vs 83.3%, p = 0.022) presented better LC rates. Concomitant 
boost did not improve 3-year LC, but increased the rate of 
TRG1 and TRG1-2 patients (Pearson's chi-squared test : p = 
0.002 and p = 0.04, repsectively). 
 
Conclusion: CRT delivered using HT and daily IGRT is safe 
and effective in the treatment of LARC patients. Longer 
followup time and prospective series are needed to confirm 
our results. Concomitant boost increase the rate of complete 
or nearly complete pathological response. The impact of TRG 
on the LC could probably assessed on after a longer followup 
time. 
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Purpose or Objective: To evaluate safety and feasibility of 
SIB-IMRT with VMAT combined with chemotherapy as 
exclusive treatment in patients with anal cancer. Early 
response is a secondary endpoint. 
 
Material and Methods: From November 2010 to June 2015, 
16 consecutive patients with histological diagnosis of anal 
squamous cells carcinoma underwent to chemoradiation in 
our center. Patients’ characteristics are described in Table 1. 
Radiation schedule consisted of 52-58 Gy in 2-Gy daily 
fractions to High Risk Volume (HR), 49.95-54 Gy to 
Intermediate Risk Volume (IR) and 45-48 Gy to Low Risk 
Volume. Daily dose fraction was around 1.65 and 1.75 for LR 
and IR respectively. One patient received a radiation boost 
up to 66 Gy after 60 days from the end of chemoradiation 
due to a poor objective response. HR, IR and LR delineation 
was performed according to AIRO guidelines published in 
2012 and reviewed in 2014. Organs at Risk (OAR) were: 
bladder, bilateral femoral heads and small bowel. All 
treatment plans were obtained with VMAT technique. SIB was 
calculate by Oncentra Inverse Planning System. In the first 3 
patients was performed a split course radiation schedule to 
reduce toxicity risk. Target objectives were minimum 
coverage by 95% isodose and maximum dose of 107% within 
the volume. OARs’ constraints were those suggested by AIRO 
guidelines (femoral heads: V52<10%; small bowel V45< 195cc; 
bladder: V60<50%). Median follow-up was 13 months (3-55). 
Concomitant chemotherapy is described in table 1.  
 
 
 
Acute Toxicity, according to RTOG criteria, was weekly 
recorded during radiotherapy course and monthly in the first 
three months of follow-up. 
 
Results: Target coverage and organ at risk sparing were 
optimal in all plans (fig1).  
 
 
During chemioradiation none of patients developed G3 
Gastroenteric toxicity (6 G1; 7 G2) and Genitourinary side 
effects were extremely rare (1 G1; 1 G2). Skin toxicity was 
the most important adverse event registered (8 G2; 4 G3). All 
chemotherapy schedule were well tolerated such the 
